This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -8.33% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Precigen, Inc. (PGEN) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 32.56% and 124.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of -7.69% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of -140% and 67.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 5.08% and 39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Precigen, Inc. (PGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
by Zacks Equity Research
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
3 Synthetic Biology Stocks in Focus With Strong Potential
by Indrajit Bandyopadhyay
Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.
Is the Options Market Predicting a Spike in Precigen (PGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Precigen (PGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.
Precigen, Inc. (PGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 16.67% and 49.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?